ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,117.33
0.40%
Dow Jones
43,408.47
0.32%
Gold vs US Dollar
2,665.00
0.47%
Brent Oil
74.055
1.67%
Bitcoin
98,009.44
3.87%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Genfit (GNFT)

  7. Genfit (GNFT) News

Genfit (GNFT)

Genfit
Date:
Sort by:
 Showing the most relevant articles for your search:EU:GNFT
DateTimeSourceHeadlineSymbolCompany
13/11/202421:10GlobeNewswire Inc.GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024EU:GNFTGenfit
07/11/202421:10GlobeNewswire Inc.GENFIT Reports Third Quarter 2024 Financial InformationEU:GNFTGenfit
23/09/202405:30GlobeNewswire Inc.GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated ApprovalEU:GNFTGenfit
19/09/202420:10GlobeNewswire Inc.GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate UpdateEU:GNFTGenfit
26/07/202411:45GlobeNewswire Inc.GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary CholangitisEU:GNFTGenfit
17/06/202420:10GlobeNewswire Inc.GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque  EU:GNFTGenfit
17/06/202420:10GlobeNewswire Inc.GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASHEU:GNFTGenfit
17/06/202420:10GlobeNewswire Inc.GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASHEU:GNFTGenfit
10/06/202421:22GlobeNewswire Inc.GENFIT : Étape historique franchie avec l'approbation accélérée d'Iqirvo® d’Ipsen dans la Cholangite Biliaire Primitive par la FDA américaineEU:GNFTGenfit
10/06/202421:22GlobeNewswire Inc.GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary CholangitisEU:GNFTGenfit
10/06/202421:22GlobeNewswire Inc.GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary CholangitisEU:GNFTGenfit
29/05/202420:10GlobeNewswire Inc.GENFIT présentera ses dernières avancées dans l'ACLF à l'EASL Congress™ 2024  EU:GNFTGenfit
29/05/202420:10GlobeNewswire Inc.GENFIT to Present Latest ACLF Research at EASL Congress™ 2024EU:GNFTGenfit
29/05/202420:10GlobeNewswire Inc.GENFIT to Present Latest ACLF Research at EASL Congress™ 2024EU:GNFTGenfit
22/05/202416:05GlobeNewswire Inc.GENFIT: May 22, 2024 Combined Shareholders Meeting ResultsEU:GNFTGenfit
22/05/202416:05GlobeNewswire Inc.GENFIT : Résultats de l’Assemblée Générale Mixte du 22 mai 2024EU:GNFTGenfit
22/05/202416:05GlobeNewswire Inc.GENFIT: May 22, 2024 Combined Shareholders Meeting ResultsEU:GNFTGenfit
14/05/202420:10GlobeNewswire Inc.GENFIT : Information financière du premier trimestre 2024EU:GNFTGenfit
14/05/202420:10GlobeNewswire Inc.GENFIT Reports First Quarter 2024 Financial InformationEU:GNFTGenfit
14/05/202420:10GlobeNewswire Inc.GENFIT Reports First Quarter 2024 Financial InformationEU:GNFTGenfit
25/04/202420:10GlobeNewswire Inc.GENFIT : Publication du rapport de performance extra-financière 2024 (exercice 2023)EU:GNFTGenfit
25/04/202420:10GlobeNewswire Inc.GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)EU:GNFTGenfit
25/04/202420:10GlobeNewswire Inc.GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)EU:GNFTGenfit
15/04/202420:10GlobeNewswire Inc.GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsEU:GNFTGenfit
15/04/202420:10GlobeNewswire Inc.GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires EU:GNFTGenfit
15/04/202420:10GlobeNewswire Inc.GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsEU:GNFTGenfit
05/04/202418:00GlobeNewswire Inc.GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FEU:GNFTGenfit
05/04/202418:00GlobeNewswire Inc.GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FEU:GNFTGenfit
05/04/202418:00GlobeNewswire Inc.GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023EU:GNFTGenfit
04/04/202420:10GlobeNewswire Inc.GENFIT : Résultats financiers annuels 2023 et point sur les activités de la SociétéEU:GNFTGenfit
 Showing the most relevant articles for your search:EU:GNFT

Your Recent History

LSE
VAST
Vast Resources
LSE
POS
Plexus
LSE
SYME
Supply@me Capital
LSE
LIO
Liontrust Asset Management
LSE
MIN
Minoan
LSE
STX
Shield Therapeutics
LSE
GGP
Greatland Gold
LSE
ITM
Itm Power
LSE
POLX
Polarean Imaging
LSE
TERN
Tern
LSE
LLOY
Lloyds Banking
LSE
MTRO
Metro Bank
LSE
NEXN
Nexxen
LSE
DEC
Diversified Energy
LSE
JD.
Jd Sports Fashion
LSE
AAZ
Anglo Asian Mining
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06